Telix Pharmaceuticals Limited
NASDAQ: TLX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christian Behrenbruch
- Employees
- 1,136
- Headquarters
- North Melbourne, Australia
- IPO year
- 2024
- Market cap
- $3.7B
- Website
- https://telixpharma.com
Loading TLX…
Loading profile data…Frequently asked questions about TLX
What does Telix Pharmaceuticals Limited (TLX) do?
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-...
Where does TLX trade?
Telix Pharmaceuticals Limited (TLX) trades on the NASDAQ.
What sector is TLX in?
Telix Pharmaceuticals Limited (TLX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Telix Pharmaceuticals Limited?
Christian Behrenbruch is the chief executive officer of Telix Pharmaceuticals Limited (TLX).
Where is Telix Pharmaceuticals Limited headquartered?
Telix Pharmaceuticals Limited is headquartered in Australia.
Does TLX pay a dividend?
Telix Pharmaceuticals Limited (TLX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TLX go public?
Telix Pharmaceuticals Limited (TLX) completed its initial public offering in 2024.